Evidence map›Paper›PMID 39422551›Full record

ReviewBlood cancer discovery2024

A View of Myeloid Transformation through the Hallmarks of Cancer.

Inés Fernández-Maestre, Sheng F Cai, Ross L Levine

Abstract readReview
In one paragraph

Review in Blood cancer discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Aging and immunity: the age-old tango.Genes & development · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Inés Fernández-MaestreHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6683-1892
Sheng F CaiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2708-887X
Ross L LevineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-7884-1905

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
Synergistic role of signaling and epigenetics in leukemic transformationR35CA197594 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ross L Levine · 2017 to 2026
$11.4M
Investigating apoptotic priming as a determinant of sensitivity to leukemia-directed therapiesK08CA241371 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAI, SHENG · 2021 to 2024
$1.0M
uNDERSTANDING AND TARGETING SENESCENCE IN CLONAL HEMATOPOIESISK00CA284253 · NCI · COLD SPRING HARBOR LABORATORY · PI FERNANDEZ MAESTRE, INES · 2025 to 2025
$101k
Identifying Inflammatory Mediators of Clonal HematopoiesisF99CA284253 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FERNANDEZ MAESTRE, INES · 2023 to 2024
$75k
NCI NIH HHS F99 CA284253NCI NIH HHS K00 CA284253NCI NIH HHS K08 CA241371NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA197594
6 · The paper itself

Abstract

The development of myeloid malignancies is influenced by a range of cell-intrinsic and cell-extrinsic factors, which can be conceptualized using the hallmarks of cancer. Although many facets of myeloid transformation are similar to those in solid tumors, there are also notable differences. Unlike solid tumors, hematologic malignancies typically exhibit fewer genetic mutations, which have been well characterized. However, understanding the cell-extrinsic factors contributing to myeloid malignancies can be challenging due to the complex interactions in the hematopoietic microenvironment. Researchers need to focus on these intricate factors to prevent the early onset of myeloid transformation and develop appropriate interventions. Significance: Myeloid malignancies are common in the elderly, and acute myeloid leukemia has an adverse prognosis in older patients. Investigating cell-extrinsic factors influencing myeloid malignancies is crucial to developing approaches for preventing or halting disease progression and predicting clinical outcomes in patients with advanced disease. Whereas successful intervention may require targeting various mechanisms, understanding the contribution of each cell-extrinsic factor will help prioritize clinical targets.

Indexed as

Cell Transformation, NeoplasticHumansLeukemia, Myeloid, AcuteMyeloproliferative DisordersNeoplasmsTumor Microenvironment

Identifiers

PMID39422551
PMCPMC11528188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.